Considering the future changes in the market environment, the Alfresa Group has formulated "10-12 Medium-term Management Plan Advancement and Expansion—Next Stage" for the period from April 1, 2010 to March 31, 2013.
10-12 Medium-term Management Plan
(1.36MB)
Outline of "10-12 Medium-term Management Plan Advancement and Expansion—Next Stage"
Target Management Indices
| Year ending March 31, 2013 Targets |
|
|---|---|
| Net sales (consolidated) | ¥2.4 trillion |
| Operating income margin (consolidated) | 1.2% |
| Net income margin (consolidated) | 0.8% |
| SG&A expenses ratio (wholesaling business) | 5.7% |
| EBITDA (manufacturing business) | 15.0% |
Medium-term Management Plan Basic Policies
(1) Reinforce efforts toward realizing the Healthcare Consortium
- Expand business scale and business domains
- Promote ties among Group businesses and with outside companies
(2) Expand the wholesaling business network and pursue value added
- Ethical pharmaceuticals wholesaling business
- Establish a nationwide marketing network and strengthen community-based marketing
- Pursue efficient management and enhancement of functions
- Realize a total customer support system
- Wholesaling business for self-medication products
- Establish a nationwide marketing network and build up the business foundations
- Realize a total lifestyle-proposing wholesaler through corporate alliances
(3) Build up the foundations for growth for the manufacturing business
- Expand contract manufacturing
- Enhance the product lineup and expand indications
- Pursue functions as a complex medical manufacturer
(4) Develop overseas business
- Establish and expand the business foundations in the Chinese market
- Actively develop business in the Asia-Pacific region
(5) Advance CSR-oriented management based on sincere business activities
- Reliable, safe and sincere business development
- Thorough implementation of internal controls by standardizing operations within the Group, etc.
Policy on Return to Shareholders
The Alfresa Group's policy is to determine return to shareholders based on consolidated financial results, with a target of an annual DOE (dividend on equity) of 2% or more, comprehensively considering the stability of the management base and future business expansion.
![]()


